Insider Trading February 13, 2026

WEX COO Executes Option Exercise, Sells Shares After Strong Q4 Results

Robert Deshaies nets proceeds from option exercise and sale as company posts Q4 2025 beat; shares slip in premarket trading

By Ajmal Hussain WEX
WEX COO Executes Option Exercise, Sells Shares After Strong Q4 Results
WEX

WEX Inc.'s Chief Operating Officer, Robert Joseph Deshaies, exercised options and sold the resulting shares on February 11, 2026, realizing proceeds of $171,312 from the sale and $79,670 from the option exercise. The transactions leave Deshaies with 15,699 shares. Separately, WEX reported better-than-expected fourth-quarter 2025 results, though the stock fell 2.63% in premarket trading amid broader market concerns.

Key Points

  • WEX COO Robert Joseph Deshaies exercised options for 1,032 shares at $77.20 and sold 1,032 shares at $166.00 on February 11, 2026, resulting in proceeds of $79,670 from the exercise and $171,312 from the sale.
  • Following the transactions, Deshaies directly owns 15,699 shares of WEX common stock.
  • WEX reported Q4 2025 adjusted EPS of $4.11 and revenue of $672.9 million, both above consensus estimates, yet shares fell 2.63% in premarket trading attributed to broader market concerns.

Insider transactions

Robert Joseph Deshaies, serving as Chief Operating Officer, Benefits at WEX Inc. (NYSE: WEX), completed a paired option exercise and share sale on February 11, 2026. On that date, Deshaies sold 1,032 shares of WEX common stock at $166.00 per share, producing total proceeds of $171,312.

On the same day, Deshaies exercised stock options that allowed him to acquire 1,032 shares at an exercise price of $77.20 per share. The exercise had a total value of $79,670. After these transactions, Deshaies directly holds 15,699 shares of WEX common stock.


Company financials and market reaction

In related corporate developments, WEX reported fourth-quarter 2025 results that topped Wall Street estimates. The company posted adjusted earnings per share of $4.11, compared with a consensus forecast of $3.90. Revenue for the quarter came in at $672.9 million, ahead of the projected $659.01 million.

Despite the earnings and revenue beats, WEX shares declined 2.63% in premarket trading. The report attributes this drop to broader market concerns rather than company-specific headline metrics.


Context and limitations

The transactions and quarterly results are presented here as reported. The public disclosures specify the quantity of shares sold and acquired, the per-share prices, and the post-transaction shareholdings for the COO. The earnings release supplies the adjusted EPS and revenue figures alongside the market consensus numbers and the noted premarket movement. The reporting does not provide further detail on motivations behind the option exercise or the insider sale, nor does it expand on the particular market factors behind the premarket decline beyond the general description of broader market concerns.

This summary is focused on the factual sequence of the insider transactions, WEX’s reported quarterly performance, and the immediate market response as stated in the filings and announcements.

Risks

  • The company’s shares fell 2.63% in premarket trading despite an earnings and revenue beat, indicating sensitivity to broader market conditions - this affects equity investors and market participants.
  • The public disclosures do not specify the rationale behind the COO’s option exercise or share sale, leaving uncertainty about any internal motives or timing considerations - this introduces informational risk for shareholders.
  • Attribution of the stock decline to broader market concerns is general; absent more detailed market context, it is unclear how durable the share reaction will be - this creates short-term price risk for traders and investors.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026